🇺🇸 FDA
Patent

US 12419890

Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors

granted A61KA61K2039/505A61K31/505

Quick answer

US patent 12419890 (Administration of sumo-activating enzyme inhibitor and checkpoint inhibitors) held by Takeda Pharmaceutical Company Limited expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Takeda Pharmaceutical Company Limited
Grant date
Tue Sep 23 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K2039/505, A61K31/505, A61K31/506, A61K39/39558